Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
Globe Newswire•16/11/2026•16:11 ET
0
Key Highlights
- ➤iLet Bionic Pancreas integration with Eversense 365 commercially launches
- ➤Eversense 365 provides one year of glucose monitoring with one sensor
- ➤iLet autonomously determines and delivers insulin doses without carb counting*
- ➤Launch meets companies’ previously announced Q4 2026 timeline
- ➤Future Mint tubeless patch pump integration planned to broaden delivery options
Expert Statements
Brian Hansen, Chief Commercial Officer of Senseonics
“Diabetes is different for everyone and we believe people should have the freedom to choose the combination of technology that works best for their lives.”
Brian Hansen, Chief Commercial Officer of Senseonics
“This launch gives our users another compelling AID option and represents another important step in expanding choice around the world’s first and only one-year CGM.”
Brian Hansen, Chief Commercial Officer of Senseonics
“We have already seen Eversense 365 demonstrate its suitability for AID in real-world use and are excited to build on that experience with Beta Bionics.”
Mark Hopman, Chief Commercial Officer of Beta Bionics
“We believe simplifying diabetes management is key to reducing the daily burden of diabetes.”
Mark Hopman, Chief Commercial Officer of Beta Bionics
“We are delighted to have moved so quickly with Senseonics from announcing our partnership to bringing this new innovation to people with diabetes.”
Mark Hopman, Chief Commercial Officer of Beta Bionics
“Integrating these two advanced technologies combines an accurate long-term sensing option with an AID that makes 100% of insulin dosing decisions, helping to reduce the constant work and decision-making that can come with managing diabetes.”
Eversense 365 now works with iLet, combining a year of accurate glucose monitoring with fully adaptive, automated insulin delivery to reduce the demands of managing diabetes
Launch expands choice for people with diabetes, and delivers on the companies’ previously announced Q4 2026 launch timeline
Get started
Create a free account to read the full story.
